Myungmoon Phar Market Cap ($25.63 Million)
Market Cap & Net Worth: Myungmoon Phar (017180)
Myungmoon Phar market cap. Myungmoon Phar (KO:017180) has a market capitalization of $25.63 Million (₩37.82 Billion) as of November 4, 2026. Listed on the KO stock exchange, this Korea-based company holds position #24113 globally and #1697 in its home market, demonstrating a -7.17% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Myungmoon Phar's stock price ₩1114.00 by its total outstanding shares 33953454 (33.95 Million). Also see 017180 operating cash flow for how efficiently the company converts equity into cash flow.
Myungmoon Phar Market Cap History (2015–2026)
Myungmoon Phar market cap history from 2015 to 2026. Data shows change from $56.82 Million to $25.63 Million (-7.26% CAGR). Check today's stock price for Myungmoon Phar for real-time trading data and today's change.
Myungmoon Phar Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Myungmoon Phar's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Myungmoon Phar (017180) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Myungmoon Phar's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.02x
Myungmoon Phar's market cap is 0.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $115.90 Million | $142.18 Billion | $6.75 Billion | 0.00x | 0.02x |
| 2017 | $131.08 Million | $140.14 Billion | $7.81 Billion | 0.00x | 0.02x |
| 2018 | $116.34 Million | $147.50 Billion | $988.27 Million | 0.00x | 0.12x |
| 2019 | $109.28 Million | $149.35 Billion | -$20.40 Billion | 0.00x | N/A |
| 2020 | $167.28 Million | $127.85 Billion | -$27.64 Billion | 0.00x | N/A |
| 2021 | $108.84 Million | $144.76 Billion | -$6.86 Billion | 0.00x | N/A |
| 2022 | $66.04 Million | $152.13 Billion | $7.87 Billion | 0.00x | 0.01x |
| 2023 | $52.58 Million | $169.57 Billion | -$4.52 Billion | 0.00x | N/A |
| 2024 | $41.85 Million | $186.44 Billion | -$3.03 Billion | 0.00x | N/A |
| 2025 | $42.57 Million | $195.25 Billion | $1.90 Billion | 0.00x | 0.02x |
Competitor Companies of 017180 by Market Capitalization
Companies near Myungmoon Phar in the global market cap rankings as of November 4, 2026. Also see 017180 total asset value for a full breakdown of the balance sheet.
Key companies related to Myungmoon Phar by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #534 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #580 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #534 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.90 |
| #580 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.03 Billion | CN¥49.31 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Myungmoon Phar (2015–2026)
Market capitalization of Myungmoon Phar from 2015 to today. Between 2015 and today, Myungmoon Phar's market cap moved from $56.82 Million to $ 25.63 Million, with a yearly change of -7.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩25.63 Million | -39.78% |
| 2025 | ₩42.57 Million | +1.70% |
| 2024 | ₩41.85 Million | -20.39% |
| 2023 | ₩52.58 Million | -20.38% |
| 2022 | ₩66.04 Million | -39.32% |
| 2021 | ₩108.84 Million | -34.94% |
| 2020 | ₩167.28 Million | +53.08% |
| 2019 | ₩109.28 Million | -6.07% |
| 2018 | ₩116.34 Million | -11.25% |
| 2017 | ₩131.08 Million | +13.10% |
| 2016 | ₩115.90 Million | +103.98% |
| 2015 | ₩56.82 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Myungmoon Phar was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $25.63 Million USD |
| MoneyControl | $25.63 Million USD |
| MarketWatch | $25.63 Million USD |
| marketcap.company | $25.63 Million USD |
| Reuters | $25.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Myungmoon Phar
MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hype… Read more